<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949767</url>
  </required_header>
  <id_info>
    <org_study_id>CN166-001</org_study_id>
    <secondary_id>EUDRACT # is 2009-010220-26</secondary_id>
    <nct_id>NCT00949767</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects</brief_title>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-866949 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics
      and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint is safety and tolerability evaluated by VS, ECG, clinical lab assessments and AEs</measure>
    <time_frame>up to Day 14 +/- 2 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose pharmacokinetics parameters of BMS-866949 [Cmax, Tmax, T-HALF, AUC (0-T), AUC (INF)] will be analyzed using blood samples</measure>
    <time_frame>Blood samples will be taken up to 144 hour post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-866949 (Panel 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-866949</intervention_name>
    <description>(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days</description>
    <arm_group_label>BMS-866949 (Panel 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(Matching volume) - Oral Solution, Oral, once 14 days</description>
    <arm_group_label>BMS-866949 (Panel 1)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 2)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 3)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 4)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 5)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 6)</arm_group_label>
    <arm_group_label>BMS-866949 (Panel 7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male 18-55

          -  Women not of child bearing potential, 18-55

        Exclusion Criteria:

          -  History of or current treatment for psychiatric illnesses, substance abuse or
             dependence

          -  History of a clinically significant neurological disorder (e.g., history of stroke,
             head trauma, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <zip>751 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

